Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 10/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446490 | 0.85 | BACE1 (0.38) | PGRKDM5BBACE1MAPKAPK2 | |
| SCHEMBL449840 | 0.82 | BACE1 (0.42) | BACE1MAPKAPK2 | |
| SCHEMBL2552657 | 0.73 | PGR (0.39) | PGRKDM5BBACE1MAPKAPK2TDP2 | |
| SCHEMBL446794 | 0.73 | BACE1 (0.39) | PGRBACE1AKR1B1 | |
| SCHEMBL429255 | 0.73 | BACE1 (0.57) | BACE1 | |
| SCHEMBL448377 | 0.72 | PGR (0.45) | PGRKDM5BMAPKAPK2TDP2PARP10 | |
| SCHEMBL445570 | 0.71 | BACE1 (0.37) | PGRBACE1MAPKAPK2 | |
| SCHEMBL2554654 | 0.71 | PGR (0.38) | PGRKDM5BBACE1TDP2AKR1B1 | |
| SCHEMBL427954 | 0.68 | BACE1 (0.53) | BACE1 | |
| SCHEMBL448434 | 0.64 | MAOB (0.46) | PGRKDM5BMAPKAPK2PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | PGR 3400/4885KDM5B 4530/4885BACE1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.